Navigation Links
NuVasive Appoints New Chief Financial Officer and Announces Additional Management Updates
Date:11/6/2009

obal biologics market, the $1.5 billion international market, and is developing products for the emerging motion preservation market.

NuVasive's principal product offering is based on its Maximum Access Surgery, or MAS® platform. The MAS platform combines four categories of products that collectively minimize soft tissue disruption during spine surgery with maximum visualization and safe, easy reproducibility for the surgeon: NeuroVision®, a proprietary software-driven nerve avoidance system; MaXcess®, a unique split-blade retractor system; a wide variety of specialized implants; and several biologic fusion enhancers. MAS significantly reduces surgery time and returns patients to activities of daily living much faster than conventional approaches. Having redefined spine surgery with the MAS platform's lateral approach, known as eXtreme Lateral Interbody Fusion, or XLIF®, NuVasive has built an entire spine franchise. With nearly 50 products today spanning lumbar, thoracic and cervical applications, the Company will continue to expand and evolve its offering predicated on its R&D focus and dedication to outstanding service levels supported by a culture of Absolute Responsiveness®.

For more information about NuVasive, go to www.nuvasive.com

NuVasive cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive's results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties that could cause actual growth and results to differ materially include, but are not limited to: the uncertain process of seeking regulatory approval or clearance for NuVasive's products
'/>"/>

SOURCE NuVasive, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. NuVasive to Present at the Oppenheimer 20th Annual Healthcare Conference
2. NuVasive Announces Conference Call and Webcast of Third Quarter 2009 Results
3. NuVasive to Present at the JMP Securities Healthcare Focus Conference
4. Cardiac Science Appoints Healthcare Executive Ronald A. Andrews, Jr. to Board of Directors
5. Company Appoints New SVP, Marketing for PBM Business
6. Kendle Appoints J. Michael Sprafka, MPH, PhD, Vice President, Kendle Consulting
7. Qforma Appoints Erin McLaughlin as Director, Field Operations
8. VitaminSpice Appoints Dr. Richard F. Seelig as Director
9. Santaris Pharma A/S Expands Executive Team, Appoints Chief Medical Officer and Chief Business Officer to Advance Proprietary RNA-targeted Drug Development Programs
10. NGM Biopharmaceuticals Appoints Dr. Arthur D. Levinson, Former Genentech CEO, to its Board of Directors
11. Peregrine Pharmaceuticals Appoints Former Genentech Senior Executive Dr. Robert Garnick as Head of Regulatory Affairs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... Research and Markets  has announced the addition of the ... offering. http://photos.prnewswire.com/prnh/20130307/600769 ... pain in the human body,s joints such as wrists, fingers, ... the tissues that surround the joints and in other organs. ... usually just mild pain around the joints coupled with stiffness ...
(Date:7/28/2014)... July 28, 2014  Syneron Medical Ltd. (NASDAQ: ... announced today that its new PicoWay® device has received ... and colors and pigmented lesions on any skin type. ... with 532nm and 1064nm wavelengths, which utilizes Syneron,s proprietary ... pulses which are trillionths of a second, known as ...
(Date:7/28/2014)... Concord Medical Services Holdings Limited ("Concord Medical" ... leading specialty hospital management solution provider and operator of ... in China , today announced that ... a special cash dividend of US$0.30 per ordinary share ... Company,s outstanding ordinary shares. The total expense for the ...
Breaking Medicine Technology:Global Rheumatoid Arthritis Drugs Market 2014-2018 2Syneron Announces CE Mark for PicoWay Dual Wavelength Picosecond Laser for Tattoo Removal and Treatment of Pigmented Lesions 2Syneron Announces CE Mark for PicoWay Dual Wavelength Picosecond Laser for Tattoo Removal and Treatment of Pigmented Lesions 3Syneron Announces CE Mark for PicoWay Dual Wavelength Picosecond Laser for Tattoo Removal and Treatment of Pigmented Lesions 4Concord Medical Declares Special Dividend 2
... Feb. 14, 2012 Glenveigh Medical  announced today that ... its request for orphan drug designation for a potential ... compound, digoxin immune fab (ovine) , is an ... toxicity. Glenveigh, a nationally renowned life science company, has ...
... 14, 2012 ZONARE Medical Systems, Inc., a developer ... of Timothy A. Marcotte to President and Chief Executive ... served as Chief Operating Officer with responsibility for the ... the company,s Chief Financial Officer.  Prior to ZONARE, he ...
Cached Medicine Technology:Nationally Recognized Glenveigh Medical Announces Orphan Drug Designation for Treatment for Severe Preeclampsia and Eclampsia 2ZONARE Medical Systems Announces Appointment of Timothy A. Marcotte as President and Chief Executive Officer 2
(Date:7/28/2014)... 28, 2014 Cape Regional Medical ... Exchange technology solution in an effort to ... support collaboration with their New Jersey health information ... center located in New Jersey, serves the local ... a variety of inpatient and outpatient services. With ...
(Date:7/28/2014)... News) --,The more chronic medical conditions people have at ... a new study claims. Since nearly four ... at Johns Hopkins Bloomberg School of Public Health in ... in life expectancy are slowing in the United States. ... kidney disease and heart failure is now the norm ...
(Date:7/28/2014)... Steven Reinberg HealthDay Reporter ... have dementia and heart rhythm irregularities are more likely to ... found. In fact, the study of more than 16,000 ... percent more likely to get a pacemaker than those without ... study is why folks with dementia are so much more ...
(Date:7/28/2014)... Washington, NY (PRWEB) July 28, 2014 Parker ... many years fighting to ensure that the heroes of 9/11 ... Fund (VCF) has announced an important deadline. According to a ... were diagnosed with a covered cancer on or before October ... October 12, 2014. First responders and others who were allegedly ...
(Date:7/28/2014)... JOLLAWhen you,re expecting somethinglike the meal you,ve ordered ... unique electrical rhythms sweep through your brain. ... they reflect a symphony of cellsboth excitatory and ... role has been debated, gamma waves have been ... the patterns have been tied to schizophrenia, Alzheimer,s ...
Breaking Medicine News(10 mins):Health News:Cape Regional Medical Center Chooses Summit Provider Exchange to Connect With NJSHINE and Physician Offices 2Health News:Cape Regional Medical Center Chooses Summit Provider Exchange to Connect With NJSHINE and Physician Offices 3Health News:Chronic Medical Conditions Can Shorten Seniors' Lives: Study 2Health News:Pacemakers Common for Those With Dementia and Irregular Heartbeats 2Health News:Pacemakers Common for Those With Dementia and Irregular Heartbeats 3Health News:October 12, 2014 Deadline Approaching for 9/11 First Responders Suffering from Certain Cancers to Submit Their Registration to the VCF, Parker Waichman LLP Comments 2Health News:October 12, 2014 Deadline Approaching for 9/11 First Responders Suffering from Certain Cancers to Submit Their Registration to the VCF, Parker Waichman LLP Comments 3Health News:Memory relies on astrocytes, the brain's lesser known cells 2Health News:Memory relies on astrocytes, the brain's lesser known cells 3
... grant of Rs.190 million ($4.17 million) to prevent the ... agreement to this effect was signed by US Ambassador ... (WHO) representative to India Salim Habayeb. ,The ... India undertake research and implement the national disease control ...
... has given GlaxoSmithKline PLC's anti-seizure medicine to treat Primary ... ,According to GlaxoSmithKline, the U.K. pharmaceutical company, the drug, ... and older, as well as adults. ,PGTC ... occurring type of generalized seizures, seen in about 20% ...
... Drug Administration takes days to track down the source of ... sensor that can enable growers to do the job themselves ... engineering at Drexel University, has developed an “intelligent” sensor technology ... dollars, the sensor can provide a result within 10 minutes ...
... most rural counties of the United States are hospitalized ... //by HHS Agency for Healthcare Research and Quality and ... Ambulatory Pediatrics. ,The study, which was led by ... of health care, health status, and other measures for ...
... anthrax attacks in the United States in 2001 had the ... the anthrax used//, belonged to the common variety, though lethal ... into the source of anthrax that reportedly killed five people ... 11 twin tower disaster. ,The Anthrax which claimed ...
... The Good Shepherd Medical Center in Oregon is providing healthy ... eating habits.// Foods from wild salmon to local organic foods ... a topping of antioxidant-rich dried cherries. , Angela ... Hermiston, OR for five days recently for the delivery of ...
Cached Medicine News:Health News:Local Health Care Limited for Rural Children 2
... The Gellhorn Pessary is used ... degree prolapse, or procidentia. It ... base and comes in nine ... Gellhorn easily folds over for ...
... 450,000 people in,the United States die ... a defibrillation shock,quickly during an episode ... that passes, the chance of,survival decreases ... Association,and JCAHO recommend that AEDs be ...
... The BioArc™ System treats female urinary stress ... using either a suprapubic (BioArc™ SP) or ... is an innovative hybrid system combining synthetic ... hybrid sling currently available. The BioArc utilizes ...
... Proven tension-free sling technology ... porcine acellular collagen matrix sling, ... tissue-to-tissue contact between sling and ... urethral or vaginal abrasion or ...
Medicine Products: